AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX)

Historical Holders from Q1 2022 to Q3 2025

Symbol
ANTX on Nasdaq
CUSIP
037326105
Type / Class
Equity / Common Stock and Warrants
Shares outstanding
27.5M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
8.28M
Holdings value
$10.5M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
35
Number of buys
9
Number of sells
-13
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Coastlands Capital Partners LP 9.3% $3.63M 2.82M Coastlands Capital LP May 28, 2025
Adjuvant Global Health Technology Fund, L.P. 7.9% $3.06M 2.37M Adjuvant Capital GP, L.P. Dec 31, 2024
Easom Eric 6.2% $2.44M 1.89M Eric Easom Dec 31, 2024
Almitas Capital LLC 5.2% $1.81M 1.43M Almitas Capital LLC Sep 30, 2025
Brii Biosciences Ltd 3.1% $1.2M 927K Brii Biosciences Limited Dec 31, 2024
BML Investment Partners, L.P. 1.4% -84.5% $551K -$3.6M 427K -86.7% BML Investment Partners, L.P. Jun 17, 2025

Institutional Holders of AN2 Therapeutics, Inc. - Common Stock and Warrants (ANTX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 8.28M $10.5M +$7.41K $1.27 35
2025 Q2 8.28M $8.78M -$8.6M $1.06 36
2025 Q1 14.3M $19.5M -$265K $1.36 37
2024 Q4 14.5M $20.1M +$893K $1.38 37
2024 Q3 13.5M $14.5M -$16.3M $1.07 31
2024 Q2 19.4M $41.7M -$1.46M $2.15 45
2024 Q1 18.7M $60.9M -$18M $3.25 54
2023 Q4 20.4M $418M +$9.59M $20.49 51
2023 Q3 19.9M $320M +$133M $16.08 37
2023 Q2 11.7M $99.9M +$18.1M $8.50 30
2023 Q1 9.6M $94.8M -$1.57M $9.87 37
2022 Q4 9.76M $93M -$3.68M $9.53 35
2022 Q3 9.5M $165M +$1.94M $17.38 35
2022 Q2 9.39M $72.4M +$2.2M $7.75 32
2022 Q1 8.95M $134M +$134M $15.07 18